AstraZeneca: Q3 2014 Results (AstraZeneca) - Nov 9, 2014 - Anticipated completion of P2 trial in Japan for moderate to severe ulcerative colitis in Q2 2015; Anticipated external presentation of P2 data in Japan for moderate to severe ulcerative colitis in 2016; Anticipated completion of enrollment in P2 trial in Japan for moderate to severe ulcerative colitis in Q1 2015
Anticipated enrollment status • Anticipated P2 data • Anticipated trial completion date • Immunology • Inflammatory Bowel Disease
|